Market Overview
A common surgical procedure to treat refractory glaucoma is called laser-assisted perforation (LAP), and it has shown great success in relieving patients of their symptoms. For most patients, the surgical process takes less than an hour and can be performed under local anesthesia. Once the surgery is over, most patients are sent home with topical medications to help relieve their discomfort. Some patients choose to try a course of antibiotics in order to relieve symptoms, but these medications do little to control topics and only provide short-term solutions. In most cases, patients in the eastern province
Request Here For PDF Brochure With Latest Insights @ https://www.coherentmarketinsights.com/insight/request-pdf/71
Market Dynamics
Increasing prevalence of glaucoma and diabetes is expected to boost the global refractory glaucoma treatment market growth over the forecast period. According to the BrightFocus Foundation, a non-profit organization, in 2020, over 80 million people were living with glaucoma across the globe, which is expected to increase to 111 million by 2040. According to the World Health Organization (WHO), the number of people with diabetes has increased from 108 million in 1980 to 422 million in 2014. As a result of this, the demand for adequate treatment options worldwide has increased massively.
However, side-effects associated with products and strict regulatory product approval policies are expected to hamper the global refractory glaucoma treatment market growth over the forecast period.
The outbreak of the COVID-19 pandemic has impacted the global refractory glaucoma treatment market. With stringent regulations on physical distancing and many countries adopting lockdown policies, the market witnessed a major decline. However, governments of several countries have started easing the lockdown regulations, which could provide key opportunities for market players to regain the lost traction.
Key Takeaways
- Among regions, North America is expected to witness significant growth in the global refractory glaucoma treatment market over the forecast period. This is owing to the presence of well-established healthcare infrastructure in the region.
-
Key companies involved in the global refractory glaucoma treatment market are Aerie Pharmaceuticals Inc., Akorn, Incorporated, Abbvie Inc. (Allergan Plc), Bausch Health (Bausch & Lomb Incorporated), Inotek Pharmaceuticals, Merck & Co., Inc., Novartis AG, Pfizer Inc., and Santen Pharmaceutical Co., Ltd.
Get Sample Report With Latest Covid19 Analysis @ https://www.coherentmarketinsights.com/insight/request-sample/71
Reasons to Purchase this Report
• Current and future of global Refractory Glaucoma Treatment Market outlook in the developed and emerging markets
• The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.
• Regions/countries that are expected to witness the fastest growth rates during the forecast period
• The latest developments, market shares, and strategies that are employed by the major market players
Access research reports that are tailored specifically for you and your organization in order to explore practical growth strategies and recommendations
Purchase This Premium Report To Access Full Information @ https://www.coherentmarketinsights.com/insight/buy-now/71
Table of Content
Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Refractory Glaucoma Treatment Market Size Analysis from 2021 to 2028
11.6 COVID-19 Outbreak: Refractory Glaucoma Treatment Industry Impact
Chapter 2 Global Refractory Glaucoma Treatment Competition by Types, Applications, and Top Regions and Countries
2.1 Global Refractory Glaucoma Treatment (Volume and Value) by Type
2.3 Global Refractory Glaucoma Treatment (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global Refractory Glaucoma Treatment Sales, Consumption, Export, Import by Regions (2016-2021)
Chapter 5 North America Refractory Glaucoma Treatment Market Analysis
Chapter 6 East Asia Refractory Glaucoma Treatment Market Analysis
Chapter 7 Europe Refractory Glaucoma Treatment Market Analysis
Chapter 8 South Asia Refractory Glaucoma Treatment Market Analysis
Chapter 9 Southeast Asia Refractory Glaucoma Treatment Market Analysis
Chapter 10 Middle East Refractory Glaucoma Treatment Market Analysis
Chapter 11 Africa Refractory Glaucoma Treatment Market Analysis
Chapter 12 Oceania Refractory Glaucoma Treatment Market Analysis
Chapter 13 South America Refractory Glaucoma Treatment Market Analysis
Chapter 14 Company Profiles and Key Figures in Refractory Glaucoma Treatment Business
Chapter 15 Global Refractory Glaucoma Treatment Market Forecast (2021-2027)
Chapter 16 Conclusions
Research Methodology
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837